AMD3100 is a CXCR7 ligand with allosteric agonist properties

Molecular Pharmacology

Volumn 75, Issue 5, 2009, Pages 1240-1247

  Kalatskaya, Irina ^a,b   Berchiche, Yamina A ^a,b   Gravel, Stéphanie ^a,b   Limberg, Brian J ^c   Rosenbaum, Jan S ^c,d   Heveker, Nikolaus ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d CincyTechUSA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; HOMODIMER; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ARRESTINS; CELLS, CULTURED; CHEMOKINE CXCL12; DIMERIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LUMINESCENCE; RECEPTORS, CXCR; RECEPTORS, CXCR4;

EID: 66049128598     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053389     Document Type: Article

References (38)

1. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, and Locati M (2008) Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29:280-286.
2. Ayoub MA, Levoye A, Delagrange P, and Jockers R (2004) Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 66:312-321. (Pubitemid 38989488)
3. Babcock GJ, Farzan M, and Sodroski J (2003) Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor. J Biol Chem 278:3378-3385. (Pubitemid 36801253)
4. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, and Bachelerie F (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280:35760-35766. (Pubitemid 41532769)
5. Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, Mortari F, Alizon M, Tsang M, and Doms RW (2001) Antigenically distinct conformations of CXCR4. J Virol 75:8957-8967. (Pubitemid 32851900)
6. Berchiche YA, Chow KY, Lagane B, Leduc M, Percherancier Y, Fujii N, Tamamura H, Bachelerie F, and Heveker N (2007) Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and Gαi activation. J Biol Chem 282:5111-5115. (Pubitemid 47093712)
7. Berger EA, Murphy PM, and Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700. (Pubitemid 29241137)
8. Bouvier M, Heveker N, Jockers R, Marullo S, and Milligan G (2007) BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods 4:3-4; author reply 4. (Pubitemid 46029461)
9. Brelot A, Heveker N, Montes M, and Alizon M (2000) Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275:23736-23744. (Pubitemid 30624660)
10. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203:2201-2213. (Pubitemid 44352240)
11. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, and Price JE (2005) CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65:6493-6497. (Pubitemid 41060680)
12. De Clercq E (2005) Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 5:805-824. (Pubitemid 41167497)
13. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754. (Pubitemid 41500740)
14. Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL, et al. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 72:588-596. (Pubitemid 44163295)
15. Gerlach LO, Jakobsen JS, Jensen KP, Rosenkilde MR, Skerlj RT, Ryde U, Bridger GJ, and Schwartz TW (2003) Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry 42:710-717. (Pubitemid 36133295)
16. Gerlach LO, Skerlj RT, Bridger GJ, and Schwartz TW (2001) Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276:14153-14160. (Pubitemid 37391801)
17. Gupta SK, Pillarisetti K, Thomas RA, and Aiyar N (2001) Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 78:29-34. (Pubitemid 32709903)
18. Hamdan FF, Audet M, Garneau P, Pelletier J, and Bouvier M (2005) High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 10:463-475. (Pubitemid 41233225)
19. Hatse S, Princen K, Bridger G, De Clercq E, and Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527:255-262. (Pubitemid 35253875)
20. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37:1253-1262. (Pubitemid 39281506)
21. Jensen PC, Thiele S, Ulven T, Schwartz TW, and Rosenkilde MM (2008) Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283:23121-23128.
22. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927. (Pubitemid 41637694)
23. Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319:710-723.
24. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, and Alizon M (1998) Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381-6388. (Pubitemid 28323949)
25. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
26. 2- adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 277:44925-44931.
27. Pattarozzi A, Gatti M, Barbieri F, Würth R, Porcile C, Lunardi G, Ratto A, Favoni R, Bajetto A, Ferrari A, et al. (2008) 17β-Estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 73:191-202. (Pubitemid 350294210)
28. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, Bouvier M, and Heveker N (2005) Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280:9895-9903. (Pubitemid 40395837)
29. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, and Ratajczak J (2006) The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20:1915-1924. (Pubitemid 44614878)
30. Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, and Schwartz TW (2004) Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 279:3033-3041. (Pubitemid 38114296)
31. Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128.
32. Terrillon S and Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep 5:30-34. (Pubitemid 38228524)
33. Thelen M and Thelen S (2008) CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol 198:9-13.
34. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
35. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 100:10782-10787. (Pubitemid 37140105)
36. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277:24515-24521.
37. Zhou N, Luo Z, Luo J, Liu D, Hall JW, Pomerantz RJ, and Huang Z (2001) Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem 276:42826-42833. (Pubitemid 37370958)
38. Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14:181-185. (Pubitemid 38586743)